IPCCC Classification of Congenital Heart Disease and Most Common Diagnoses
1. Introduction
Congenital heart disease (CHD) is the most common human congenital defect, and a leading cause of death in infants. With an incidence that varies between 0.8 to 2% in neonates, congenital heart disease contributes to a much larger fraction of stillbirths.(Goldmuntz 2001; Loffredo 2000) Additionally, undiagnosed mild malformations of the heart often appear later in adulthood or remain undiagnosed for life. If these are included, some expect a prevalence of CHD that is up to 4% among all newborns.(Loffredo 2000) An additional contributor to the rising prevalence of CHD among adults is the advance in diagnostics and medical and surgical treatments of children with CHD, which is allowing them, in the majority of cases, to get their heart defect, fixed and sustain a normal life into adulthood.(van der Bom and others 2011) Management of the increasing number of adult patients living with CHD is becoming more and more complicated due to the fact that many patients with mild cardiac lesions are missed during childhood and later appear with complications due to these defects such as heart failure, but even more due to the improvements in diagnosis and surgical care of pediatric patients which are allowing them to survive to adulthood and have their own children.
The majority of CHD is thought to result from gene mutations. This was suggested by early observations of Mendelian inheritance of CHD in families. Another evidence came from congenital syndromes due to micro and macro deletions of chromosomal regions that would result in CHD together with several other manifestations. Over the past few decades, and with the advent of gene sequencing and other techniques it became possible to identify the genetic causes of CHD.(Goldmuntz 2001) In syndromic cases, although it was possible to identify the chromosomal deletions causing the disease, in many cases the gene responsible for the heart phenotype remains undefined. Other syndromes were found to be due to single gene defects; however, for the majority, the downstream pathophysiology linking the gene defect to the development of disease remains obscure. In parallel, extensive
The understanding of how defects in these genes cause CHD turned out to be more complicated that initially expected. It became evident that not all CHD manifests true Mendelian inheritance. It is possible that combinations of mutations in different genes result in a particular phenotype, or combination of a gene mutation with a particular environmental exposure results in a CHD phenotype. Mutations might have low penetrance and only serve to increase the risk of CHD. Other mutations might yield totally defective proteins, yet be compensated for by other proteins in interlinked pathways. Copy Number Variations (CNVs), altered transcription, somatic mutations, and microRNA (miRNA) are also additional mechanisms through which the molecular basis of CHD can be explained. Current research explores all of these mechanisms with a wide array of technologies that are better than ever, and hence the future decade promises a near complete understanding of heart development and the genetic basis of Congenital Heart Disease.
This chapter covers the genetics of syndromic and non-syndromic congenital heart disease. It discusses all genes that have been associated with congenital heart disease in humans with depiction of the spectrum of mutations and the genotype-phenotype correlations for each. The chapter also covers the roles of CNVs, epigenetics, somatic mutations, and miRNA in CHD. Current technologies and strategies used to understand the genetics of congenital heart disease are also discussed. The chapter ends with an explanation of how these technologies can unravel the genetics of CHD and allow the application of research findings for the benefit of patients.
2. Classifications, anatomy, and clinical significance
Congenital heart disease encompasses a broad category of anatomic malformations, which can range from a small septal defect or leaky valve to a severe malformation requiring extensive surgical repair or leading to death such as a single ventricle. Several classification systems exist for describing congenital heart disease. The most common classification used to describe CHD is purely clinical whereby CHD is cyanotic if the malformation results in deoxygenated blood bypassing the lung and causes cyanosis (blue patient), or non-cyanotic if the malformation does not result in cyanosis. The most common cyanotic heart defects are Tetralogy of Fallot (TOF), Hypoplastic Left Heart Syndrome (HLHS), Transposition of the Great Arteries (TGA), Truncus Arteriosus (TA), and Total Anomalous Pulmonary Venous Connection (TAPVC). Congenital heart defects can also be simple or complex. A complex malformation includes several simple malformations occurring together. The most typical example is Tetralogy of Fallot, which -as its name implies- includes four malformations: Pulmonary Stenosis (PS), an overriding aorta, Ventricular Septal Defect (VSD), and right ventricular hypertrophy. Because of the wide diversity in the anatomy of the cardiac malformations, several detailed morphological classifications were also developed. The most widely recognized one is the International Pediatric and Congenital Cardiac Code (IPCCC), which was developed by the International Society for Nomenclature of Paediatric and Congenital Heart Disease (ISNPCHD). Table 1 shows the categories of CHD classifications of the IPCCC with the most common diagnoses within each category. The detailed version could be downloaded from the IPCCC website (www.ipccc.net). Other classification systems are radiologic based on echocardiography or magnetic resonance imaging, hemodynamic based on shunts and circulations in the heart, or embryological based on the presumed origin during heart development. CHD can occur as part of a syndrome and as such is labeled as syndromic or nonsyndromic, both of which are discussed in this chapter. In syndromic and non-syndromic cases, CHD can be isolated, that is occurring in a single patient, or familial afflicting many members within the same family. The recurrence rate of CHD after an isolated case is 2.7%. (Gill and others 2003)
This anatomical heterogeneity of CHD has been one major reason why we know little about its genetics. Beyond the anatomical classification described in the IPCCC, different combinations of malformations and variations to described malformations can occur. Pediatric cardiologists often end up using different terminologies to describe similar defects because of their complexity. Extremely rare complex malformations are also sometimes described and run in families while their cause remains unknown.(Herrera and others 2008; Jaeggi and others 2008) Genotype-phenotype correlations are hard to establish due to this heterogeneity. In the majority of familial cases of CHD, there are different types of structural malformations within the same family. The same single gene mutation has been shown to cause a variety of cardiac defects, even within the same family.(Goldmuntz 2001) Whenever mouse knockout models were developed to recapitulate a human CHD phenotype, the mouse phenotype was not always similar to that seen in humans.(Bruneau 2008) All these issues raised the hypothesis of a multifactorial and perhaps polygenetic origin of CHD. The genetic background of the individual, in-utero environment, epigenetic changes, and embryological hemodynamics and physiology are all possible causes of this phenotypic heterogeneity.
Being a leading cause of deaths in the first year of life, CHD has prompted a large wave of development in surgical and interventional procedures to treat CHD. As such, CHD is mostly corrected with surgical and interventional procedures when the malformation causes symptoms or can cause heart failure such as a large septal defect or a cyanotic heart disease. Small malformations such as tiny septal defects that are expected to correct on their own or to not cause any complication are simply observed. With the recent advances in treatment, the mortality from CHD has decreased tremendously and most CHD patients survive a normal life throughout adulthood.(van der Bom and others 2011) This prompted a whole new subspecialty in adult cardiology to take care of adult patients with CHD.(Moodie 1994) As these adults with CHD are planning to have children of their own, the recurrence risk became a problem, and this was yet another force to identify the genetic causes behind the disease, given that genetic counseling and pre-implantation genetic diagnosis (PGD) can be useful tools for these parents.
Abnormalities of position and connection of the heart | Dextrocardia Atrial Situs Inversus Double Inlet Left Ventricle (DILV); Double Inlet Right Ventricle (DIRV) Transposition of the Great Arteries (TGA) Double Outlet Left Ventricle (DORV); Double Outlet Right Ventricle (DORV) Common Arterial Trunk (CAT), aka Truncus Arteriosus (TA) |
Tetralogy of Fallot and variants | Tetralogy of Fallot (TOF) Pulmonary Atresia (PA) and Venticular Septal Defect (VSD) |
Abnormalities of great veins | Supervior Vena Cava (SVC) Abnormality Inferior Vena Cava (SVC) Abnormality Coronary Sinus Abnormality Total Anomalous Pulmonary Venous Connection (TAPVC) Partially Anomalous Pulmonary Venous Connection (PAPVC) |
Abnormalities of atriums and atrial septum | Atrial Septal Defect (ASD) Patent Foramen Ovale (PFO) |
Abnormalities of AV valves and AV septal defect | Tricuspid Regurgitation (TR) Tricuspid Stenosis (TS) Ebstein’s Anomaly Mitral Regurgitation (MR) Mitral Stenosis (MS) Mitral Valve Proplapse (MVP) Atrioventricular Septal Defect (AVSD) |
Abnormalities of ventricles and ventricular septum | Single Ventricle Ventricular imbalance: dominant LV +hypoplastic RV, or dominant RV+hypoplastic RV Aneurysm (RV, LV, or septal) Hypoplastic Left Heart Syndrome (HLHS) Double Chambered Right Ventricle (DCRV) Ventricular Septal Defect (VSD) |
Abnormalities of VA valves and great arteries | Aortopulmonary Window (AP Window) Pulmonary Stenosis (PS), valvar or subalvar Pulmonary Artery Stenosis (PAS) Aortic Stenosis (AS), valvar or suvalvar Aortic Insufficiency (AI) Bicuspid Aortic Valve (BAV) Supravalvar Aortic Stenosis (SVS) Coarctation of the Aorta (COA) Interrupted Aortic Arach (IAA) |
Abnormalities of coronary arteries, arterial duct and pericardium; AV fistulae | Anomalous Origin of Coronary Artery from Pulmonary Artery (ALCAPA) Patent Ductus Arteriosus (PDA) |
3. Developmental genetics of congenital heart disease
Heart development is crucial to understand because its molecular basis is evolutionary conserved as depicted by studies in several model organisms. Heart development is a complex process regulated by combinatorial interactions of transcription factors and their regulators, ligands and receptors, signaling pathways, and contractile protein genes among others. The differential expression of each of these genes at unique stages of development and in different areas of the heart is responsible for the normal development of the heart. Any disruption in these genes will result in congenital malformations of the heart. This molecular program for heart development has been a heavy field of research, yet our knowledge is far from being complete.
The heart is the first organ to develop in the embryo at the second week of gestation when pre-cardiac lateral plate mesoderm cells migrate towards the midline of the embryo and form two crescent-shaped primordia, which fuse to form a beating heart tube at week 3. Within only few days the heart tube folds on itself in a process known as looping. This is the first event in the organogenesis of the embryo that manifests left-right asymmetry and is believed to be at the origin of the laterality program of the embryo. Subsequently, the four chambers of the heart are formed. This requires the differentiation of myocytes into two different subtypes, atrial and ventricular. Finally, valves and septa form through divisions within the heart to form the mature four-chambered heart. Valvulogenesis and septogenesis both require interaction between endocardial and myocardial cells, and valvoseptal malformations are the most common CHDs. In addition, development of the conduction system occurs into pacemakers and purkinjie cells, as well as vascularization from neural crest cells, and coronary arteries from epicardial precursor cells. As such, heart development requires a complex interplay of cell-commitment, migration, proliferation, differentiation, and apoptosis. Any perturbation in this program can result in congenital heart disease.
Transcription factors regulate this tight program of gene expression, which is chamber-, and stage-specific. Protein interactions and formation of complexes that regulate downstream targets cardiac targets with convergent and divergent pathways have made the understanding of the molecular basis of CHD complicated. In-vitro and in-vivo studies have been crucial in widening our understanding of the molecular program for heart development. Major transcription factor families involved in heart development include the GATA, T-box, homeobox, and basic Helix-Loop-Helix (bHLH) among others. Screening of human CHD patients for gene mutations within these transcription factor families as well as other cardiac-enriched genes implicated in heart development has not been as rewarding. Mutations in
This gap has prompted novel directions in understanding the genetics of CHD. One of the hypotheses is the multifactorial and polygenetic nature of CHD, with gene mutations acting on a certain genetic background or acting within a particular susceptible environment within a developmental window. There have been efforts towards a new systems biology approach to understanding CHD. In addition to germline DNA sequencing which comprises the majority of the literature, somatic DNA sequencing, RNA sequencing, study of microRNAs (miRNAs), and Copy Number Variations (CNVs) analysis are becoming more popular tools to study CHD. Also with the advent of next-generation sequencing and the decreased cost of both sequencing and array comparative genomic hybridization (array-CGH), more data are becoming available, and the molecular biology approach of the past few decades is shifting into a bioinformatics approach to help decipher the genetics of this complex disease. The subsequent sections of the chapter will dwell into the genetics of CHD from the oldest and most known to the most recent and least known. The below section discusses syndromic CHD, which comprises entities where the genetic causes is the most well established. Then the genes implicated in non-syndromic CHD in humans will be discussed with the degree of evidence for each. The most recent but least developed technologies to understand CHD mentioned above will be discussed at the end of the chapter.
4. Syndromic congenital heart disease
Cardiac malformations are among the most prevalent malformations in congenital syndromes. A large list of syndromes with congenital heart disease as a common manifestation has known genetic defects. CHD syndromes can be either due chromosome dosage disorders, large chromosomal deletions, small micro-deletions, or single gene defects. Table 2 shows a list of CHD syndromes within each of these categories with the corresponding genetic defect. This section will discuss the most common syndromes that include congenital heart disease as a primary manifestation. Within each syndrome, the phenotypic diversity as well as the spectrum of mutations and chromosomal defects that have been reported will be discussed.
4.1. Down Syndrome (trisomy 21)
Down Syndrome is the most common disorder of chromosome dosage with an incidence of 1 in 700 to 1 in 800 live births. The incidence is known to increase tremendously with increased maternal age, particularly above the age of 35. The main clinical manifestations of Down Syndrome are characteristic dysmorphic facies, mental retardation, premature ageing, congenital heart disease, hearing loss, and increased risk of hematologic malignancies.(Pueschel 1990)
Trisomy 21 (Down Syndrome) | Unknown |
Turner | Unknown |
Di Georges Syndrome | 22q11.2 deletion resulting in absent |
Williams-Beuren Syndrome | Microdeletion of |
Holt-Oram Syndrome | |
Alagille Syndome | |
Noonan Syndrome | Mutations in |
CHARGE Association | Mutations in |
Char Syndrome | Mutations in |
Ellis-can Creveld Syndrome | Mutations in |
Cardiofaciocutaneous Syndrome | Mutations in |
Costello Syndrome | Mutations in |
Marfan Syndrome | Mutations in |
Congenital Heart Disease occurs in 40 to 50% of Down Syndrome patients. The most common abnormality is Atrioventricular Septal Defect (AVSD).(Marino 1993) Other malformations include VSD and TOF among others. Some CHD phenotypes are not seen in Down Syndrome patients such as Transposition of the Great Arteries (TGA) and Situs Inversus.(Marino 1993) Adult patients with Down Syndrome are also predisposed to Mitral Valve Prolapse (MVP) and fenestrations in the cusps of the aortic and pulmonary valves. (Hamada and others 1998)
Given the complexity of the phenotype in Down Syndrome, there has been tremendous effort to build a phenotype map and identify the genetic cause behind each phenotype.(Delabar and others 1993; Korenberg and others 1994) Although successful for other features of Down Syndrome, the cause of the cardiac malformations in Down Syndrome are still unclear. Knowing that
4.2. Turner Syndrome
Turner syndrome is a condition in females where all or part of one sex chromosome is absent. It is estimated to occur in 1 of 2500 females.(Bondy 2009) It manifests most commonly with characteristic physical features such as short stature, webbed necks, broad chest, low hairline, and low set ears, gonadal dysfunction, and cognitive deficits.(Bondy 2009) Clinical features are highly variable and can sometimes be very mild. Congenital heart disease is found in 20% to 50% of Turner Syndrome patients. The most common malformation is a Coarctation of the Aorta (COA) of the postductal type, which comprises 50% to 70% of CHD in Turner Syndrome.(Doswell and others 2006) Other cardiac malformations seen in Turner Syndrome include Bicuspid Aortic Valve (BAV), Partial Anomalous Pulmonary Venous Connection (PAPVC), and Hypoplastic Left Heart (HLH). In addition, a higher frequency of cardiac conduction abnormalities, hypertension, and aortic dilation has been reported in Turner Syndrome patients.(Doswell and others 2006; Lopez and others 2008) The molecular mechanisms leading to the cardiac malformations in Turner Syndrome are not clear.
4.3. Di George Syndrome
Di George Syndrome (DGS) is also known as Velocardiofacial Syndrome (VCFS) or Chromosome 22q11.2 Deletion Syndrome. It is caused by a 1.5 to 3.0-Mb hemizygous deletion on chromosome 22 q11, which can be inherited in an autosomal dominant fashion, but most commonly arises
4.4. Williams-Beuren Syndrome
Williams-Beuren Syndrome (WBS) results from a hemizygous deletion of 1.5 to 1.8 Mb on chromosome 7q11.23, an area that encompasses 28 genes. Its prevalence is estimated to be 1 in 7500.(Stromme and others 2002) Clinically, patients have Supravalvular Aortic Stenosis (SVAS), mental retardation, characteristic facial features, distinctive dental anomalies, infantile hypercalcemia, and peripheral pulmonary artery stenosis.(Beuren and others 1962; Grimm and Wesselhoeft 1980; Williams and others 1961) The cardiac phenotype of vascular stenosis is caused by haploinsufficiency of the Elastin (
4.5. Holt-Oram Syndrome
Holt-Oram Syndrome (HOS) is also known as Heart-Hand Syndrome, and it manifests as congenital heart disease and upper limb dysplasia. The heart manifestations are mostly septal malformations and include secundum ASD, VSD, patent ductus arteriosus, and conduction system abnormalities. The upper limb malformations are widely variable but are typically bilateral and asymmetric in severity. They can range from a small abnormality such as a distally-placed thumb to phocomelia or hypoplasia of the shoulders and clavicles. Sometimes the upper limb dysplasia can go unnoticed and will be seen only after radiological imaging. Congenital heart malformations occur in 85% of HOS patients.(Basson and others 1994; Boehme and Shotar 1989)
Genetically, HOS is an autosomal dominant disease caused by mutations in the
Genotype-phenotype correlations were also performed in HOS, and it has been shown that
4.6. Alagille Syndrome
Alagille Syndrome is inherited in an autosomal dominant fashion and is defined in the presence of intrahepatic bile duct paucity that usually manifests as cholestasis, congenital heart disease, distinctive facies, skeletal, ocular, renal, and neurological abnormalities.(Kamath and others 2011; Li and others 1997a) CHD is found in more than 90% of patients with Alagille Syndrome and the most common lesion is Pulmonary Atery Stenosis (PAS) or hypoplasia. Other common lesions include TOF, pulmonary valve stenosis (PS), and ASD.(McElhinney and others 2002) The prevalence of the disease is estimated at around one in 700,000 neonates when presence of jaundice is used to ascertain cases (Danks and others 1977), but in fact the disease has a tremendous variability in the phenotype and variable penetrance in families so that the actual prevalence is expected to be much higher.
Alagille Syndrome is caused by mutations in the
Clinical testing for
4.7. Noonan Syndrome
Noonan Syndrome (NS) is a dysmorphic cardiofacial syndrome inherited mostly in an autosomal dominant fashion, with some cases occurring sporadically. Its incidence ranges between 1 in 1000 to 1 in 2500 live births.(Tartaglia and others 2010) The characteristic physical features are downward eyeslanting of the eyes, hypertelorism, low-set ears, short stature, short and webbed neck, and epicanthic folds.(Tartaglia and others 2010) Congenital Heart Disease is found in 80 to 90% of patients with Noonan Syndrome and valvar pulmonary stenosis (PS) and Hypertrophic Cardiomyopathy (HCM) are the two most common cardiac manifestations. A large set of cardiac malformations can also occur including secundum ASD, AVSD, TOF, COA, VSD, PDA, and mitral valve disease.(Marino and others 1999; Noonan 1994) Patients might also have deafness, cryptorchidism, motor delay, and bleeding diathesis.(Tartaglia and others 2010)
NS is a genetically heterogeneous syndrome with at least 8 genes that have been associated with the disease so far:
Disease penetrance is almost complete with
5. Nonsyndromic congenital heart disease
Isolated congenital heart disease is the most prevalent form of CHD. Evidence for the genetic basis of isolated CHD comes from familial clustering of cases as well as higher recurrence rate of CHD. Mutations in many genes have been associated with several CHD phenotypes, yet the evidence is variable for each gene. Gene mutations can best be classified as highly penetrant mutations in disease-causing genes, low-penetrance mutations in susceptibility genes, and common variants in CHD risk-genes. Transcription factor genes are the most common group of genes implicated in CHD. Other genes are part of signaling transduction pathways and structural components of the heart. Evidence for each gene comes from family studies and segregation analyses using direct sequencing. As mentioned earlier, one of the biggest challenges in the genetics of nonsyndromic CHD is that sequencing for all genes implicated in CHD explains the genetic cause of only a small percentage of patients. Most gene mutations have been described in one or few cases, while only a small number of genes have been duplicated in many cohorts and families.
Table 3 lists all genes in which mutations have been found in different nonsyndromic CHD phenotypes. Most of these are based on only few cases and hence remain to be ascertained; however some have been duplicated in several families such as the phenotypes associated with
Dextrocardia | 9916846, 19064609, 14682828 | |
Tricuspid Atresia | 15643620, 15389319 | |
Mitral Atresia | 20730588 | |
Transposition of the Great Arteries (TGA) | 9916847, 14638541, 17924340, 11799476, 18538293, 19553149, 19933292, 19064609, 17295247, 19933292, 14681828, 18538293, 1460745420656787 | |
Double Outlet Right Ventricle (DORV) | 9916847, 17924340, 11799476, 19553149, 14681828, 20807224, 14607454 | |
Common Arterial Trunk (CAT) | 19666519, 14607454, 15649947 | |
Tetralogy of Fallot (TOF) | 20437614, 19886994, 17924340, 16470721, 18538293, 20581743, 19553149, 18538293, 18538293, 20819618, 14517948, 14607454 | |
Total Anomalous Pulmonary Venous Connection (TAPVC) | 20071345, 18273862, 19064609, 14681828 | |
Partial Anomalous Pulmonary Venous Connection (PAPVC) | 18076106 | |
ASD | 18159245, 1480002, 15689439, 12845333, 17072672, 19853937, 19666519, 16287139, 17668378, 9651244, 15810002, 15689439,14607454 | |
Ebstein ‘s Anomaly | 21127202 | |
Atrioventricular Septal Defect (AVSD) | 12845333, 20670841, 19064609, 19506109, 12632326, 15857420, 18538293, 10053005 | |
Hypoplastic Left Heart Syndrome (HLH) | 18593716, 14607454, 20456451, 11470490, 14681828 | |
VSD | 21544582, 12845333, 17253934, 18055909, 19853937, 14681828, 19853938, 16287139, 17668378, 12074273, 9651244, 10587520 | |
Pulmonary Valve Stenosis (PS) | 21080980, 9916847, 12845333, 19666519, 14681828 | |
Pulmonary Artery Stenosis (PAS) | 16944981, 11175284, 10942104, 20437614 | |
Aortic Valve Stenosis (AS) | 21080980, 16025100, 20656787 | |
Bicuspid Aortic Valve (BAV) | 16729972, 160251100 | |
Supravalvar Aortic Stenosis (SVAS) | 9215670, 16944981, 11175284 | |
Coarcation of the Aorta (COA) | 20420808, 10053005, 18593716, 14607454 | |
Interrupted Aortic Arch (IAA) | 18538293, 10053005, 14607454 | |
Patent Ductus Arteriosus (PDA) | 16444274, 17956658, 18752453 |
In the remaining part this section, the most common genes implicated in nonsyndromic CHD are discussed in details. For each gene, the mutational spectrum, function, associated CHD phenotypes, and mechanism of disease (if known) are provided. The three large groups of cardiac specific transcription factors, the GATA (
5.1. GATA transcription factors (GATA4, GATA5, GATA6 )
GATA-binding proteins are a family of transcription factors that regulate gene expression and are involved in cell differentiation, survival, and proliferation in many tissues. GATA proteins are evolutionary conserved proteins containing two zinc-finger motifs. They recognize and bind to a “GATA” consensus sequence, which is an important
Animal studies have shown that while
5.2. Homeobox transcription factors (NKX2-5, NKX2-6 )
Homeobox-containing genes are transcription factors that play crucial roles in cardiac development through regulating essential processes such as the spatio-temporal specificity of gene expression required for normal cardiac tissue differentiation. This transcription factor is evolutionary conserved and essential for cardiac development. The “
5.3. T-Box transcription factors (TBX1, TBX5, TBX20 )
The T-box family of binding proteins also consists of important transcription factors in cardiac development. T-box genes are evolutionary conserved and share a T-binding domain. All family members are involved in regulating developmental processes such as the initiation and potentiation of cardiac development.(Hariri and others 2011)
The crucial role of
Another member of the family that has been implicated in non-syndromic CHD is
5.4. Other transcription factors (CITED2, ANKRD1, FOG2, ZIC3 )
The above three families of transcription factors are the most heavily studied in heart development, however a large set of other transcription factors have also been implicated in CHD, yet with lower degrees of evidence, or for some lower penetrance. This section will briefly discuss each of these transcription factors.
Ankyrin Repeat Domain 1 (
Friend of GATA 2 (
5.5. NODAL signaling genes (NODAL, GDF1, FOXH1, CFC1, ACVR2B, LEFTY2)
The NODAL family of proteins is member of the TGF-beta superfamily of secreted signaling molecules. NODAL signaling is responsible for dorso-ventral patterning in vertebrate development as well as mesoderm and endoderm generation. Mutations in different genes in the NODAL signaling cascade are believed to occur and cumulatively decrease NODAL signaling leading to CHD phenotypes.(Roessler and others 2009) NODAL mutations have been reported in patients with heterotaxy, TGA, and conotruncal defects,(Gebbia and others 1997; Mohapatra and others 2009) but as mentioned earlier simple heterozygosity is not enough to cause the phenotype in the majority of cases. Mutations in other pathway genes such as
5.6. Notch signaling genes (NOTCH1, JAG1, NOTCH2 )
The Notch-Jagged signaling pathway is an important regulatory mechanism of cell differentiation processes during embryonic and adult life. In the heart, it is particularly important in cardiac valve development.
5.7. Contractile protein genes (MYH6, MYH7, MYH11, MYBPC3, ACTC1 )
Mutations in contractile protein genes are common causes of Hypertrophic Cardiomyopathy (HCM) and other cardiomyopathies. However, some of these genes have also been implicated in a minority of CHD cases. One
5.8. Miscellaneous genes (ELN, GJA1, FLNA, THRAP2 )
Elastin (
6. Other genetic mechanisms of CHD
Despite the large number of genes implicated in non-syndromic CHD, the genetic cause of the majority of isolated cases of CHD is still poorly understood. This has led researchers to investigate genetic mechanisms other than gene mutations that can contribute to inherited or isolated CHD. Copy Number Variations (CNVs), micro RNA (miRNA), somatic mutations, and epigenetics are all active areas of research into the genetics of CHD.
6.1. Copy Number Variations
Copy Number Variations (CNVs) are structural alterations to the genomic DNA that result in the cell having abnormal copies of large sections of its DNA. They can be inherited or occur
6.2. Micro RNA
Micro RNAs (miRNAs) are small (around 22 nucleotides long) single stranded noncoding RNAs and are encoded by miRNA genes. miRNAs serve as regulators of gene expression. Since cardiac development involves tremendous spatio-temportal specificity of gene expression, it is believed that miRNAs are involved in cardiac development and they can potentially cause CHD. miRNAs are important players in cellular proliferation, differentiation, and migration all of which are essential processes for proper cardiac development. In fact, cardiac specific miRNAs were discovered such as miR-133 and miR-1-2, both of which when knocked out in mice cause cardiac defects, specifically VSD and dilated cardiomyopathy.(Ikeda and others 2007) miR-208a and miR-208b are also cardiac-enriched, and they are encoded within the introns of
6.3. Somatic mutations
Another direction of research to assess CHD is the study of somatic mutations using surgically discarded tissues from CHD patients who undergo surgical repair. Both DNA and RNA can be extracted and sequenced. Previous studies have focused on sequencing
6.4. Epigenetics
The multifactorial causality of CHD has long been hypothesized to explain the complexity of the genetics of cardiac malformations. Epigenetics is one model where gene-environment interaction can affect gene expression and disturb developmental processes in the embryonic heart. Histone modifications and chromatin remodeling both play important roles in cardiac development and physiology(Han and others 2011; Lange and others 2008; Ohtani and Dimmeler 2011), and recent studies shoed that they can directly interact with some classes of transcription factors like the T-box family.(Miller and Weinmann 2009) It is possible that epigenetic mechanisms contribute to the etiology of CHD, however more evidence remains to be established.
7. Current tools for the genetic evaluation of CHD
Different techniques are currently available to interrogate the genetic causes of CHD. Karyotyping and Fluorescent In-Situ Hybridization (FISH) analysis remain the best tools to assess chromosomal deletions or rearrangements. They are often the starting point for the genetic assessment of a CHD patient. Whenever candidate genes are suspected, for instance in the setting of a clinically diagnosed syndrome, Sanger sequencing is performed on the candidate gene to look for disease-causing mutations. For many years, together with positional mapping through linkage analysis, these were the only tools that drove genetic discovery in CHD in humans. Current technology makes use of array-comparative genomic hybridization (array-CGH) for linkage analysis, Genome Wide Association Studies (GWAS), CNV analysis, homozygosity mapping, and transcriptome analysis. More importantly was the introduction of next-generation sequencing in 2005 and the tremendous decrease in the cost of sequencing over the past several years, which is allowing the massive sequencing of the exome and even genome of huge numbers of patients. Next-generation RNA sequencing is also beginning to be used to sequence cardiac transcripts from CHD patients who have underwent surgery. The rapid pooling of high throughput data is expected to massively increase our understanding of CHD within the coming two years. To deal with these large amounts of data, bioinformatics and modeling of genetic variants determine function is becoming the standard and many molecular biology labs are forced to become genetics and bioinformatics labs to make use of current technology. A systems biology approach is needed nowadays to integrate high throughput data from the many possible sources.
8. From the bench to the bedside
With the advances in sequencing and bioinformatics, gene discovery in CHD is escalating. This advance in research is directly translated to clinical testing to provide genetic counseling for adult patients with CHD who plan to have children. From a technical aspect, our capability to identify genetic variants in CHD genes has magnified. Nonetheless, making functional significance and even clinical sense of the large number of gene mutations remains a big challenge. Given the complexity of CHD, definite gene mutations remain uncommon. At this time when the genetic inflow of information is very fast, physician-scientists must be very careful in communicating genetic information that is not validated to patients, in order to avoid psychological and emotional harm. On a different angle, with sequencing of the exome or genome, the chances of detecting incidental findings that indicate disease risk or prognosis becomes very high. All such unintentionally detected serious genetic findings are termed the incidentalome.(Kohane and others 2006) Since CHD is mostly surgically treated and people who undergo genetic testing are often already cured, caregivers need to be cautious before rushing next-generation sequencing into the CHD clinic.
9. Future prospects
Current trends in CHD genetics research are making use of the rapidly developing technology, particularly high throughput sequencing. This trend will continue over the coming few years. The challenge is in integrating the increasing amounts of data to answer the questions that need to be answered. Systems biology and innovative bioinformatics tools are crucial to integrate data from different sources and build a pipeline that can unravel the mysteries that molecular biologists have been trying to answer for many years.
Eventually, more validated genetic information will be available in the clinic to allow accurate genetic counseling and prenatal screening. Understanding heart development will also allow for possible therapeutic applications given the many-shared molecular pathways between embryologic heart development and adult heart disease, particularly tissue death and regeneration in the setting of ischemic heart disease.
References
- 1.
Arrington C. B. Nightengale D. Lowichik A. Rosenthal E. T. Christian-Ritter K. Viskochil D. H. 2006 Pathologic and molecular analysis in a family with rare mixed supravalvar aortic and pulmonic stenosis. Pediatr Dev Pathol9 297 306 - 2.
RN Bamford Roessler. E. Burdine R. D. Saplakoglu U. dela Cruz. J. Splitt M. Goodship J. A. Towbin J. Bowers P. Ferrero G. B. others 2000 Loss-of-function mutations in the EGF-CFC gene CFC1 are associated with human left-right laterality defects. Nat Genet26 365 9 - 3.
Bamforth S. D. Braganca J. Farthing C. R. Schneider J. E. Broadbent C. Michell A. C. Clarke K. Neubauer S. Norris D. Brown N. A. others 2004 Cited2 controls left-right patterning and heart development through a Nodal-Pitx2c pathway. Nat Genet36 1189 96 - 4.
Basson C. T. Bachinsky D. R. Lin R. C. Levi T. Elkins J. A. Soults J. Grayzel D. Kroumpouzou . E. Traill T. A. Leblanc-Straceski J. others 1997 Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram syndrome. Nat Genet15 30 5 - 5.
Basson C. T. Cowley G. S. Solomon S. D. Weissman B. Poznanski A. K. Traill T. A. Seidman J. G. CE Seidman 1994 The clinical and genetic spectrum of the Holt-Oram syndrome (heart-hand syndrome). N Engl J Med330 885 91 - 6.
Basson C. T. Huang T. Lin R. C. Bachinsky D. R. Weremowicz S. Vaglio A. Bruzzone R. Quadrelli R. Lerone M. Romeo G. others 1999 Different TBX5 interactions in heart and limb defined by Holt-Oram syndrome mutations. Proc Natl Acad Sci U S A96 2919 24 - 7.
Bauer R. C. Laney A. O. Smith R. Gerfen J. Morrissette J. J. Woyciechowski S. Garbarini J. Loomes K. M. Krantz I. D. Urban Z. others 2010 Jagged1 (JAG1) mutations in patients with tetralogy of Fallot or pulmonic stenosis. Hum Mutat31 594 601 - 8.
Beuren A. J. Apitz J. Harmjanz D. 1962 Supravalvular aortic stenosis in association with mental retardation and a certain facial appearance. Circulation26 1235 40 - 9.
Boehme DH, Shotar AO. 1989 A complex deformity of appendicular skeleton and shoulder with congenital heart disease in three generations of a Jordanian family. Clin Genet36 442 50 - 10.
Bondy CA. (2009). Turner syndrome 2008 Horm Res 71 Suppl1 52 6 - 11.
Breckpot J. Thienpont B. Arens Y. Tranchevent L. C. Vermeesch J. R. Moreau Y. Gewillig . M. Devriendt K. 2011 Challenges of interpreting copy number variation in syndromic and non-syndromic congenital heart defects. Cytogenet Genome Res135 251 9 - 12.
Britz-Cunningham SH, Shah MM, Zuppan CW, Fletcher WH. 1995 Mutations of the Connexin43 gap-junction gene in patients with heart malformations and defects of laterality. N Engl J Med332 1323 9 - 13.
Bruneau BG. 2008 The developmental genetics of congenital heart disease. Nature451 943 8 - 14.
BS Budde Binner. P. Waldmuller S. Hohne W. Blankenfeldt W. Hassfeld S. Bromsen J. Dermintzoglou A. Wieczorek M. May E. others 2007 Noncompaction of the ventricular myocardium is associated with a de novo mutation in the beta-myosin heavy chain gene. PLoS One 2,e1362. - 15.
Callis T. E. Pandya K. Seok H. Y. Tang R. H. Tatsuguchi M. Huang Z. P. Chen J. F. Deng Z. Gunn B. Shumate J. others 2009 MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest119 2772 86 - 16.
Chen Y. Han Z. Q. Yan W. D. Tang C. Z. Xie J. Y. Chen H. Hu D. Y. 2010 A novel mutation in GATA4 gene associated with dominant inherited familial atrial septal defect. J Thorac Cardiovasc Surg140 684 7 - 17.
Ching Y. H. Ghosh T. K. Cross S. J. Packham E. A. Honeyman L. Loughna S. Robinson T. E. Dearlove A. M. Ribas G. Bonser A. J. others 2005 Mutation in myosin heavy chain 6 causes atrial septal defect. Nat Genet37 423 8 - 18.
Cinquetti R. Badi I. Campione M. Bortoletto E. Chiesa G. Parolini C. Camesasca C. Russo A. Taramelli R. Acquati F. 2008 Transcriptional deregulation and a missense mutation define ANKRD1 as a candidate gene for total anomalous pulmonary venous return. Hum Mutat29 468 74 - 19.
Curran ME, Atkinson DL, Ewart AK, Morris CA, Leppert MF, Keating MT. 1993 The elastin gene is disrupted by a translocation associated with supravalvular aortic stenosis. Cell73 159 68 - 20.
Danks D. M. Campbell P. E. Jack I. Rogers J. Smith A. L. 1977 Studies of the aetiology of neonatal hepatitis and biliary atresia. Arch Dis Child52 360 7 - 21.
Dasgupta C. Martinez A. M. Zuppan C. W. MM Shah Bailey. L. L. Fletcher W. H. 2001 Identification of connexin43 (alpha1) gap junction gene mutations in patients with hypoplastic left heart syndrome by denaturing gradient gel electrophoresis (DGGE). Mutat Res479 173 86 - 22.
Delabar J. M. Theophile D. Rahmani Z. Chettouh Z. Blouin J. L. Prieur M. Noel B. Sinet P. M. 1993 Molecular mapping of twenty-four features of Down syndrome on chromosome 21. Eur J Hum Genet1 114 24 - 23.
Doswell B. H. Visootsak J. Brady A. N. Graham J. M. Jr 2006 Turner syndrome: an update and review for the primary pediatrician. Clin Pediatr (Phila)45 301 13 - 24.
Draus J. M. Jr MA Hauck Goetsch. M. Austin E. H. 3rd Tomita-Mitchell A. ME Mitchell 2009 Investigation of somatic NKX2-5 mutations in congenital heart disease. J Med Genet46 115 22 - 25.
El -Rassy I. Bou-Abdallah J. Al-Ghadban S. Bitar F. Nemer G. 2008 Absence of NOTCH2 and Hey2 mutations in a familial Alagille syndrome case with a novel frameshift mutation in JAG1. Am J Med Genet A146 937 9 - 26.
Emanuel BS. 2008 Molecular mechanisms and diagnosis of chromosome 22q11.2 rearrangements. Dev Disabil Res Rev14 11 8 - 27.
Esposito G. Butler T. L. Blue G. M. Cole A. D. Sholler G. F. Kirk E. P. Grossfeld P. BM Perryman Harvey. R. P. DS Winlaw 2011 Somatic mutations in NKX2 5 GATA4, and HAND1 are not a common cause of tetralogy of Fallot or hypoplastic left heart. Am J Med Genet A 155A,2416-21. - 28.
Fakhro K. A. Choi M. Ware S. M. Belmont J. W. Towbin J. A. Lifton R. P. Khokha M. K. Brueckner M. 2011 Rare copy number variations in congenital heart disease patients identify unique genes in left-right patterning. Proc Natl Acad Sci U S A108 2915 20 - 29.
Garg V. Kathiriya I. S. Barnes R. Schluterman M. K. King I. N. CA Butler Rothrock. C. R. . Eapen R. S. Hirayama-Yamada K. Joo K. others 2003 GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature 424,443 7 - 30.
Garg V. Muth A. N. Ransom J. F. Schluterman M. K. Barnes R. King I. N. Grossfeld P. D. Srivastava D. 2005 Mutations in NOTCH1 cause aortic valve disease. Nature437 270 4 - 31.
Gebbia M. Ferrero G. B. Pilia G. Bassi M. T. Aylsworth A. Penman-Splitt M. Bird L. M. Bamforth J. S. Burn J. Schlessinger D. others 1997 X-linked situs abnormalities result from mutations in ZIC3. Nat Genet17 305 8 - 32.
Gill H. K. Splitt M. Sharland G. K. Simpson J. M. 2003 Patterns of recurrence of congenital heart disease: an analysis of 6,640 consecutive pregnancies evaluated by detailed fetal echocardiography. J Am Coll Cardiol42 923 9 - 33.
Goldmuntz E. 2001 The epidemiology and genetics of congenital heart disease. Clin Perinatol28 1 10 - 34.
Goldmuntz E. Bamford R. JD Karkera dela. Cruz J. Roessler E. Muenke M. 2002 CFC1 mutations in patients with transposition of the great arteries and double-outlet right ventricle. Am J Hum Genet70 776 80 - 35.
Greenway S. C. Pereira A. C. Lin J. C. De Palma S. R. Israel S. J. Mesquita S. M. Ergul E. Conta J. H. Korn J. M. Mc Carroll S. A. others 2009 De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. Nat Genet41 931 5 - 36.
Griffin H. R. Topf A. Glen E. Zweier C. Stuart A. G. Parsons J. Peart I. Deanfield J. O’Sullivan J. Rauch A. others 2010 Systematic survey of variants in TBX1 in non-syndromic tetralogy of Fallot identifies a novel 57 base pair deletion that reduces transcriptional activity but finds no evidence for association with common variants. Heart 96,1651 5 - 37.
Grimm T. Wesselhoeft H. 1980 The genetic aspects of Williams-Beuren syndrome and the isolated form of the supravalvular aortic stenosis. Investigation of 128 families (author’s transl)]. Z Kardiol69 168 72 - 38.
Habets P. E. Moorman A. F. Clout D. E. MA van Roon Lingbeek. M. van Lohuizen M. Campione M. Christoffels V. M. 2002 Cooperative action of Tbx2 and Nkx2.5 inhibits ANF expression in the atrioventricular canal: implications for cardiac chamber formation. Genes Dev16 1234 46 - 39.
Hamada T. Gejyo F. Koshino Y. Murata T. Omori M. Nishio M. Misawa T. Isaki K. 1998 Echocardiographic evaluation of cardiac valvular abnormalities in adults with Down’s syndrome. Tohoku J Exp Med185 31 5 - 40.
Han P. Hang C. T. Yang J. CP Chang 2011 Chromatin remodeling in cardiovascular development and physiology. Circ Res108 378 96 - 41.
Hariri F. Nemer M. Nemer G. 2011 T-box factors: Insights into the evolutionary emergence of the complex heart. Ann Med. - 42.
Heathcote K. Braybrook C. Abushaban L. Guy M. ME Khetyar Patton. MA Carter N. D. Scambler P. J. Syrris P. 2005 Common arterial trunk associated with a homeodomain mutation of NKX2.6. Hum Mol Genet14 585 93 - 43.
Herrera P. CA Caldarone Forte. V. Holtby H. Cox P. Chiu P. Kim P. C. 2008 Topsy-turvy heart with associated congenital tracheobronchial stenosis and airway compression requiring surgical reconstruction. Ann Thorac Surg86 282 3 - 44.
Ikeda S. Kong S. W. Lu J. Bisping E. Zhang H. Allen P. D. Golub T. R. Pieske B. Pu W. T. 2007 Altered microRNA expression in human heart disease. Physiol Genomics31 367 - 45.
Jaeggi E. Chitayat D. Golding F. Kim P. Yoo S. J. 2008 Prenatal diagnosis of topsy-turvy heart. Cardiol Young18 337 42 - 46.
BM Kamath Podkameni. G. Hutchinson A. L. Leonard L. D. Gerfen J. Krantz I. D. Piccoli D. A. Spinner N. B. Loomes K. M. Meyers K. 2011 Renal anomalies in Alagille syndrome: A disease-defining feature. Am J Med Genet A. - 47.
JD Karkera Lee. J. S. Roessler E. Banerjee-Basu S. Ouspenskaia M. V. Mez J. Goldmuntz E. Bowers P. Towbin J. Belmont J. W. others 2007 Loss-of-function mutations in growth differentiation factor-1 (GDF1) are associated with congenital heart defects in humans. Am J Hum Genet81 987 94 - 48.
Kasahara H. Lee B. Schott J. J. Benson D. W. Seidman J. G. CE Seidman Izumo. S. 2000 Loss of function and inhibitory effects of human CSX/NKX2.5 homeoprotein mutations associated with congenital heart disease. J Clin Invest106 299 308 - 49.
Kirk E. P. Sunde M. Costa M. W. Rankin S. A. Wolstein O. Castro M. L. Butler T. L. Hyun C. Guo G. Otway R. others 2007 Mutations in cardiac T-box factor gene TBX20 are associated with diverse cardiac pathologies, including defects of septation and valvulogenesis and cardiomyopathy. Am J Hum Genet81 280 91 - 50.
Kodo K. Nishizawa T. Furutani M. Arai S. Yamamura E. Joo K. Takahashi T. Matsuoka R. Yamagishi H. 2009 GATA6 mutations cause human cardiac outflow tract defects by disrupting semaphorin-plexin signaling. Proc Natl Acad Sci U S A106 13933 8 - 51.
Kohane IS, Masys DR, Altman RB. 2006 The incidentalome: a threat to genomic medicine. JAMA296 212 5 - 52.
Korenberg J. R. Chen X. N. Schipper R. Sun Z. Gonsky R. Gerwehr S. Carpenter N. Daumer . C. Dignan P. Disteche C. others 1994 Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc Natl Acad Sci U S A91 4997 - 53.
Kyndt F. Gueffet J. P. Probst V. Jaafar P. Legendre A. Le Bouffant F. Toquet C. Roy E. Mc Gregor L. Lynch S. A. others 2007 Mutations in the gene encoding filamin A as a cause for familial cardiac valvular dystrophy. Circulation115 40 9 - 54.
Lange M. Kaynak B. Forster U. B. Tonjes M. Fischer J. J. Grimm C. Schlesinger J. Just S. Dunkel I. Krueger T. others 2008 Regulation of muscle development by DPF3, a novel histone acetylation and methylation reader of the BAF chromatin remodeling complex. Genes Dev22 2370 84 - 55.
Lepore J. J. Mericko P. A. Cheng L. MM Lu Morrisey. MS Parmacek 2006 GATA-6 regulates semaphorin 3C and is required in cardiac neural crest for cardiovascular morphogenesis. J Clin Invest116 929 39 - 56.
Li L. Krantz I. D. Deng Y. Genin A. Banta A. B. Collins C. C. Qi M. Trask B. J. Kuo W. L. Cochran J. others 1997a Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet16 243 51 - 57.
Li Q. Y. Newbury-Ecob R. A. Terrett J. A. Wilson D. I. Curtis A. R. Yi C. H. Gebuhr T. Bullen . P. J. Robson S. C. Strachan T. others 1997b Holt-Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family. Nat Genet 15,21 9 - 58.
Lin X. Huo Z. Liu X. Zhang Y. Li L. Zhao H. Yan B. Liu Y. Yang Y. Chen Y. H. 2010 A novel GATA6 mutation in patients with tetralogy of Fallot or atrial septal defect. J Hum Genet55 662 7 - 59.
Loffredo CA. 2000 Epidemiology of cardiovascular malformations: prevalence and risk factors. Am J Med Genet97 319 25 - 60.
Lopez L. Arheart K. L. Colan S. D. Stein N. S. Lopez-Mitnik G. Lin A. E. MD Reller Ventura. R. Silberbach M. 2008 Turner syndrome is an independent risk factor for aortic dilation in the young. Pediatrics 121,e1622 7 - 61.
Marino B. 1993 Congenital heart disease in patients with Down’s syndrome: anatomic and genetic aspects. Biomed Pharmacother47 197 200 - 62.
Marino B. Digilio M. C. Toscano A. Giannotti A. Dallapiccola B. 1999 Congenital heart diseases in children with Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr135 703 6 - 63.
Maslen C. L. Babcock D. Robinson S. W. Bean L. J. Dooley K. J. Willour V. L. Sherman S. L. 2006 CRELD1 mutations contribute to the occurrence of cardiac atrioventricular septal defects in Down syndrome. Am J Med Genet A140 2501 5 - 64.
McBride KL, Riley MF, Zender GA, Fitzgerald-Butt SM, Towbin JA, Belmont JW, Cole SE. 2008 NOTCH1 mutations in individuals with left ventricular outflow tract malformations reduce ligand-induced signaling. Hum Mol Genet17 2886 93 - 65.
Mc Daniell R. Warthen D. M. Sanchez-Lara P. A. Pai A. Krantz I. D. Piccoli D. A. Spinner N. B. 2006 NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet79 169 73 - 66.
Mc Elhinney D. B. Krantz I. D. Bason L. Piccoli D. A. Emerick K. M. Spinner N. B. Goldmuntz E. 2002 Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome. Circulation106 2567 - 67.
Megarbane A. Salem N. Stephan E. Ashoush R. Lenoir D. Delague V. Kassab R. Loiselet J. Bouvagnet P. 2000 X-linked transposition of the great arteries and incomplete penetrance among males with a nonsense mutation in ZIC3. Eur J Hum Genet 8,704 8 - 68.
Metcalfe K. Rucka A. K. Smoot L. Hofstadler G. Tuzler G. Mc Keown P. Siu V. Rauch A. Dean J. Dennis N. others 2000 Elastin: mutational spectrum in supravalvular aortic stenosis. Eur J Hum Genet8 955 63 - 69.
Miller SA, Weinmann AS. 2009 An essential interaction between T-box proteins and histone-modifying enzymes. Epigenetics4 85 8 - 70.
Mohamed S. A. Aherrahrou Z. Liptau H. Erasmi A. W. Hagemann C. Wrobel S. Borzym K. Schunkert H. Sievers H. H. Erdmann J. 2006 Novel missense mutations (T596M and p.P1797H) in NOTCH1 in patients with bicuspid aortic valve. Biochem Biophys Res Commun 345,1460-5. - 71.
Mohapatra B. Casey B. Li H. Ho-Dawson T. Smith L. Fernbach S. D. Molinari L. Niesh S. R. Jefferies J. L. Craigen W. J. others 2009 Identification and functional characterization of NODAL rare variants in heterotaxy and isolated cardiovascular malformations. Hum Mol Genet18 861 71 - 72.
Momma K. 2010 Cardiovascular anomalies associated with chromosome 22q11.2 deletion syndrome. Am J Cardiol105 1617 24 - 73.
28 1953 61 Monserrat L, Hermida-Prieto M, Fernandez X, Rodriguez I, Dumont C, Cazon L, Cuesta MG, Gonzalez-Juanatey C, Peteiro J, Alvarez N and others. (2007). Mutation in the alpha-cardiac actin gene associated with apical hypertrophic cardiomyopathy, left ventricular non-compaction, and septal defects. Eur Heart J 28,1953-61 - 74.
Moodie DS. 1994 Adult congenital heart disease. Curr Opin Cardiol9 137 42 - 75.
Moskowitz I. P. Kim J. B. Moore M. L. Wolf C. M. MA Peterson Shendure. J. MA Nobrega Yokota. Y. Berul C. Izumo S. others 2007 A molecular pathway including Id2, Tbx5, and Nkx2-5 required for cardiac conduction system development. Cell129 1365 76 - 76.
Muncke N. Jung C. Rudiger H. Ulmer H. Roeth R. Hubert A. Goldmuntz E. Driscoll D. Goodship J. Schon K. others 2003 Missense mutations and gene interruption in PROSIT240, a novel TRAP240-like gene, in patients with congenital heart defect (transposition of the great arteries). Circulation108 2843 50 - 77.
Nemer G. Fadlalah F. Usta J. Nemer M. Dbaibo G. Obeid M. Bitar F. 2006 A novel mutation in the GATA4 gene in patients with Tetralogy of Fallot. Hum Mutat27 293 4 - 78.
Noonan JA. 1994 Noonan syndrome. An update and review for the primary pediatrician. Clin Pediatr (Phila)33 548 55 - 79.
Oda T. Elkahloun A. G. Pike B. L. Okajima K. Krantz I. D. Genin A. Piccoli D. A. Meltzer P. S. Spinner N. B. Collins F. S. others 1997 Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet16 235 42 - 80.
Ohtani K. Dimmeler S. 2011 Epigenetic regulation of cardiovascular differentiation. Cardiovasc Res90 404 12 - 81.
Payne A. R. Chang S. W. Koenig S. N. Zinn A. R. Garg V. 2012 Submicroscopic Chromosomal Copy Number Variations Identified in Children With Hypoplastic Left Heart Syndrome. Pediatr Cardiol. - 82.
Peng T. Wang L. Zhou S. F. Li X. 2010 Mutations of the GATA4 and NKX2.5 genes in Chinese pediatric patients with non-familial congenital heart disease. Genetica138 1231 40 - 83.
Pizzuti A. Sarkozy A. Newton A. L. Conti E. Flex E. Digilio M. C. Amati F. Gianni D. Tandoi C. Marino B. others 2003 Mutations of ZFPM2/FOG2 gene in sporadic cases of tetralogy of Fallot. Hum Mutat22 372 7 - 84.
Pober BR. 2010 Williams-Beuren syndrome. N Engl J Med362 239 52 - 85.
Pober B. R. Johnson M. Urban Z. 2008 Mechanisms and treatment of cardiovascular disease in Williams-Beuren syndrome. J Clin Invest118 1606 15 - 86.
Posch M. G. Gramlich M. Sunde M. Schmitt K. R. Lee S. H. Richter S. Kersten A. Perrot A. Panek A. N. Al Khatib. I. H. others 2010 A gain-of-function TBX20 mutation causes congenital atrial septal defects, patent foramen ovale and cardiac valve defects. J Med Genet47 230 5 - 87.
Pueschel SM. 1990 Clinical aspects of Down syndrome from infancy to adulthood. Am J Med Genet Suppl7 52 6 - 88.
Rajagopal S. K. Ma Obler Q. Shen D. Manichaikul J. Tomita-Mitchell A. Boardman A. Briggs K. Garg C. Srivastava V. D. others 2007 Spectrum of heart disease associated with murine and human GATA4 mutation. J Mol Cell Cardiol43 677 85 - 89.
Reamon-Buettner S. M. Borlak J. 2004 Somatic NKX2-5 mutations as a novel mechanism of disease in complex congenital heart disease. J Med Genet41 684 90 - 90.
Reamon-Buettner S. M. Borlak J. 2010 NKX2-5: an update on this hypermutable homeodomain protein and its role in human congenital heart disease (CHD). Hum Mutat31 1185 94 - 91.
Roessler E. Ouspenskaia M. V. JD Karkera Velez. J. I. Kantipong A. Lacbawan F. Bowers P. Belmont J. W. Towbin J. A. Goldmuntz E. others 2008 Reduced NODAL signaling strength via mutation of several pathway members including FOXH1 is linked to human heart defects and holoprosencephaly. Am J Hum Genet83 18 29 - 92.
Roessler E. Pei W. Ouspenskaia M. V. JD Karkera Velez. J. I. Banerjee-Basu S. Gibney G. Lupo P. J. Mitchell L. E. Towbin J. A. others 2009 Cumulative ligand activity of NODAL mutations and modifiers are linked to human heart defects and holoprosencephaly. Mol Genet Metab98 225 34 - 93.
Sperling S. Grimm C. H. Dunkel I. Mebus S. Sperling H. P. Ebner A. Galli R. Lehrach H. Fusch C. Berger F. others 2005 Identification and functional analysis of CITED2 mutations in patients with congenital heart defects. Hum Mutat26 575 82 - 94.
Stennard F. A. Costa M. W. Lai D. Biben C. Furtado M. B. MJ Solloway Mc Culley. D. J. Leimena C. Preis J. I. Dunwoodie S. L. others 2005 Murine T-box transcription factor Tbx20 acts as a repressor during heart development, and is essential for adult heart integrity, function and adaptation. Development132 2451 62 - 95.
Stromme P. Bjornstad P. G. Ramstad K. 2002 Prevalence estimation of Williams syndrome. J Child Neurol17 269 71 - 96.
Tartaglia M. Zampino G. BD Gelb 2010 Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol1 2 26 - 97.
Tevosian S. G. Deconinck A. E. Tanaka M. Schinke M. Litovsky S. H. Izumo S. Fujiwara Y. Orkin S. H. 2000 FOG-2, a cofactor for GATA transcription factors, is essential for heart morphogenesis and development of coronary vessels from epicardium. Cell 101,729 39 - 98.
Tidyman WE, Rauen KA. 2009 The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev19 230 6 - 99.
Tomita-Mitchell A. Maslen C. L. Morris C. D. Garg V. Goldmuntz E. 2007 GATA4 sequence variants in patients with congenital heart disease. J Med Genet44 779 83 - 100.
Turbay D. Wechsler S. B. Blanchard K. M. Izumo S. 1996 Molecular cloning, chromosomal mapping, and characterization of the human cardiac-specific homeobox gene hCsx. Mol Med2 86 96 - 101.
van der Bom T. Zomer A. C. Zwinderman A. H. Meijboom F. J. Bouma B. J. Mulder B. J. 2011 The changing epidemiology of congenital heart disease. Nat Rev Cardiol 8,50 60 - 102.
van Rooij E. Sutherland L. B. Qi X. Richardson J. A. Hill J. Olson E. N. 2007 Control of stress-dependent cardiac growth and gene expression by a microRNA. Science316 575 9 - 103.
Williams JC, Barratt-Boyes BG, Lowe JB. 1961 Supravalvular aortic stenosis. Circulation24 1311 8 - 104.
Xin B. Puffenberger E. Tumbush J. Bockoven J. R. Wang H. 2007 Homozygosity for a novel splice site mutation in the cardiac myosin-binding protein C gene causes severe neonatal hypertrophic cardiomyopathy. Am J Med Genet A 143A,2662 7 - 105.
Xin M. CA Davis Molkentin. JD Lien C. L. Duncan S. A. Richardson J. A. Olson E. N. 2006 A threshold of GATA4 and GATA6 expression is required for cardiovascular development. Proc Natl Acad Sci U S A103 11189 94 - 106.
Yagi H. Furutani Y. Hamada H. Sasaki T. Asakawa S. Minoshima S. Ichida F. Joo K. Kimura M. Imamura S. others 2003 Role of TBX1 in human del22q11.2 syndrome. Lancet362 1366 73 - 107.
Yuan Z. R. Kohsaka T. Ikegaya T. Suzuki T. Okano S. Abe J. Kobayashi N. Yamada M. 1998 Mutational analysis of the Jagged 1 gene in Alagille syndrome families. Hum Mol Genet7 1363 9 - 108.
Zahka K. Kalidas K. MA Simpson Cross. H. Keller B. B. Galambos C. Gurtz K. MA Patton Crosby. A. H. 2008 Homozygous mutation of MYBPC3 associated with severe infantile hypertrophic cardiomyopathy at high frequency among the Amish. Heart94 1326 - 109.
Zhang L. Tumer Z. Jacobsen J. R. Andersen P. S. Tommerup N. Larsen L. A. 2006 Screening of 99 Danish patients with congenital heart disease for GATA4 mutations. Genet Test10 277 80 - 110.
Zhao R. Watt A. J. MA Battle Li. J. Bondow B. J. Duncan S. A. 2008 Loss of both GATA4 and GATA6 blocks cardiac myocyte differentiation and results in acardia in mice. Dev Biol317 614 9 - 111.
Zhu L. Vranckx R. Khau Van Kien. P. Lalande A. Boisset N. Mathieu F. Wegman M. Glancy L. Gasc J. M. Brunotte F. others 2006 Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet38 343 9